



Mithra Signs LSA for Commercialization of Myring™ in Switzerland

- **Mithra grants license to Labatec for commercialization of vaginal contraceptive ring in Switzerland**
- **Production of Myring™ at the Mithra CDMO facility in Belgium**
- **Agreement follows licensing deals with major international market leaders for commercialization of Myring™**

Liege, Belgium, 05 December 2019 – 7 :30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces that it has entered into a license and supply agreement with Labatec for the commercialization of its hormonal contraceptive ring Myring™ in Switzerland.

Under the terms of this agreement, Labatec will distribute Myring™ in Switzerland, where the Swiss contraceptive rings market is worth EUR 8 million per year¹. Mithra will receive an upfront payment and recurring revenues based on an agreed licensing model. Moreover, Mithra will manufacture Myring™ at its Contract Development and Manufacturing Organization facility in Belgium.

Labatec is a privately owned Swiss-based pharmaceutical delivering high quality Swiss registered products to the Swiss and Middle East North African Markets. Covering both the hospital and retail sectors, Labatec has a portfolio of over 70 products and a growing geographic footprint. Manufactured in Europe and approved by Swissmedic medicinal agency, their products represent a trusted Swiss brand of medicines in multiple therapeutic areas, including women’s health.

To date, Mithra has licensed Myring™ to industry leaders in 15 international markets, including the United States, Austria, Czech Republic, Russia, Denmark, Chile, Australia/New Zealand, MENA territories, South America, Germany, Israel, China, Belgium, Luxembourg and Switzerland. Further contracts are expected to follow in the coming months, including in Europe, where Mithra expects to have 23 marketing authorizations granted.

François Fornieri, CEO Mithra Women’s Health, commented: *“We are pleased to have finalized the agreement with Labatec for the commercialization of our hormonal contraceptive ring in Switzerland. We are also delighted to complete our expansion strategy in Europe where our product should be widely available in pharmacies next year.”*

Faisal Darwazeh, CEO Labatec Pharma, commented: *“We continue to actively license innovative European products for the Swiss and MENA markets. We are looking forward to registering and launching Myring™ in the Swiss market, adding to our growing portfolio of differentiated Women’s Health products. We look forward to work closely with Mithra on a successful launch”.*

¹ IQVIA 2017

For more information, please contact:

Alexandra Deschner (IRO) : +32 490 58 35 23 - investorrelations@mithra.com

Maud Vanderthommen (Press) : +32 473 58 61 04 – press@mithra.com

About Mithra

Mithra (Euronext: MITRA) is a Belgian biotech company dedicated to transforming Women's Health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra's goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span. Its three lead development candidates are built on Mithra's unique native estrogen platform, Estetrol (E4): Estelle®, a new era in oral contraception, PeriNesta®, the first complete oral treatment for perimenopause and Donesta®, the next-generation hormone therapy. Mithra also develops and manufactures complex therapeutics in the areas of contraception, menopause and hormone-dependent cancers. It offers partners a complete spectrum of research, development and specialist manufacturing at its technological platform Mithra CDMO. Active in more than 85 countries around the world, Mithra has an approximate headcount of 250 staff members and is headquartered in Liège, Belgium. www.mithra.com

About Myring™

Myring™ (etonogestrel/ethinyl estradiol vaginal ring) is a non-biodegradable, flexible, transparent, combination contraceptive vaginal ring, with an outer diameter of 54 mm and a cross-sectional diameter of 4 mm. It is made of ethylene vinylacetate copolymers, and contains 11.7 mg etonogestrel and 2.7 mg ethinyl estradiol. When placed in the vagina, each ring releases, in line with the originator (Nuvaring®), on average 0.120 mg/day of etonogestrel and 0.015 mg/day of ethinyl estradiol over a three-week period of use. The ring is to remain in place continuously for three weeks. It is removed for a one-week break, during which a withdrawal bleed usually occurs. A new ring is inserted one week after the last ring was removed.

About Labatec

Labatec is a privately owned Pharmaceuticals company based in Geneva Switzerland with operations in Switzerland, Portugal and Middle East North Africa region. The company is focused on the speciality retail segment of Muscle skeletal, women's health, Urology in addition to a wide portfolio of hospital products all licensed from European and Canadian companies.

Important information

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates", "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

To receive our press releases by email, please subscribe to our mailing list on investors.mithra.com